Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$266.11 +1.61 (+0.61%)
At close: Sep 4, 2026 · 4:00 PM EDT

Alnylam Pharmaceuticals (ALNY) Goodwill & Intangibles (2009 - 2012)

Alnylam Pharmaceuticals' (ALNY) quarterly Goodwill & Intangibles came in at $145000.0 in Q3 2012, down 54.4% on a YoY basis from $318000.0 in Q4 2011, and down 22.87% quarter-over-quarter from $188000.0 in Q2 2012.

Analysis

Alnylam Pharmaceuticals (ALNY) Goodwill & Intangibles (2009 - 2012) Analysis & Trends

Alnylam Pharmaceuticals (ALNY) has reported Goodwill & Intangibles for 4 consecutive years, with $145000.0 the latest figure, recorded in Q3 2012.

  • For the quarter ending Q3 2012, Goodwill & Intangibles fell 54.4% year-over-year to $145000.0; the trailing twelve-month figure through Sep 2012 stood at $145000.0 (down 54.4% YoY), and the FY2011 full-year result was $275000.0, down 38.62% from the prior year.
  • Goodwill & Intangibles eased to $145000.0 in Q3 2012 per ALNY's latest filing, from $188000.0 in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $622000.0 in Q4 2009 and bottomed at $145000.0 in Q3 2012.
  • Historically, Goodwill & Intangibles has averaged $365363.6 across 4 years, with a median of $361000.0 in 2011.
  • The sharpest annual moves came in 2010 and 2012: Goodwill & Intangibles slipped 27.97% in 2010, then sank 54.4% in 2012.
  • Over 4 years, Goodwill & Intangibles stood at $622000.0 in 2009, then retreated by 27.97% to $448000.0 in 2010, then tumbled by 38.62% to $275000.0 in 2011, then plunged by 47.27% to $145000.0 in 2012.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods registered $145000.0, $188000.0, and $231000.0 for Q3 2012, Q2 2012, and Q1 2012 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2012 145,000.00
Jun 30, 2012 188,000.00
Mar 31, 2012 231,000.00
Dec 31, 2011 275,000.00
Sep 30, 2011 318,000.00
Jun 30, 2011 361,000.00
Mar 31, 2011 405,000.00
Dec 31, 2010 448,000.00
Sep 30, 2010 491,000.00
Jun 30, 2010 535,000.00
Dec 31, 2009 622,000.00